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Bacille Calmette Guérin substrain Moreau Rio de Janeiro is an attenuated strain of Mycobacterium bovis
that has been used extensively as an oral tuberculosis vaccine. We assessed its potential as a challengeccepted 2 June 2010




model to study clinical and immunological events following repeated mycobacterial gut infection. Seven
individuals received three oral challengeswith approximately 107 viable bacilli. Clinical symptoms, T-cell
responses and gene expression patterns in peripheral blood were monitored. Clinical symptoms were
relatively mild and declined following each oral challenge. Delayed T-cell responses were observed, and
limited differential gene expression detected by microarrays. Oral challenge with BCG Moreau Rio de
Janeiro vaccine was immunogenic in healthy volunteers, limiting its potential to explore clinical innate
immune responses, but with low reactogenicity.nnate immunity
. Introduction
Mycobacterium bovis based Bacille Calmette Guérin (BCG) was
riginally introduced in the 1930s as an oral vaccine against the
uman pathogen Mycobacterium tuberculosis, the cause of tubercu-
osis. In the 1960s, most of the world moved towards intradermal
accination with lyophilized BCG, but some countries, including
razil, continued to exploit the oral vaccination route [1,2]. BCG,
hich is still available as a live vaccine, was derived by extensive
assage from M. bovis, which naturally infects humans and cattle
ia the gastrointestinal tract. Live Mycobacteria have the potential
o interact stronglywith both the innate and adaptive immune sys-
em and any vaccine based on them has the potential to be used
s a safe clinical probe of human responses [3]. Thus, BCG-based
accines can potentially provide a safe but effective tool to mimic
atural infection and stimulate both innate and acquired immu-
ity under relatively ‘natural’ conditions of gut infection. Further,
s BCG is a licensed vaccine many ethical hurdles are consequently
educed for human studies.
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Immune responses can be both protective and dangerous to
the host. For example, many of the symptoms associated with
the reactogenicity of vaccines are in fact inappropriately stimu-
lated innate responses. Innate immune responses are difﬁcult to
safely monitor in humans as approved methods for stimulating
such responses are not generally available and would raise ethi-
cal concerns. By delivering oral BCG (which has been given orally
tomillions of peoplewith a good record of safety) to healthy volun-
teers under controlled conditions we aimed to assess if this system
had value for monitoring innate immune activation. The impact
of gastrointestinal colonization by BCG was indirectly determined
by measuring antigen-speciﬁc T-cell and cytokine responses, along
with microarray analysis. Further insight was obtained by system-
atically recording clinical symptoms associated with sequential
BCG challenges such as abdominal pain, diarrhoea; upper respi-
ratory tract congestion, secretion; fever and headache. In this way,
we sought to build-up an integrated picture of innate and adap-
tive immune responses at various time points before and after a
series of bacterial challenges. We used an oral BCG preparation
(BCG Moreau Rio de Janeiro), commercially produced, which has
a strong safety record in extensive human testing [4]. We report
here data for seven subjects recruited into a pilot study to deter-
mine the feasibility of this approach, and to develop and test assays
and protocols to identify innate immune pathways associated with

























































i428 F. Schreiber et al. / Va
. Materials and methods
.1. Subjects and ethics statement
Healthy volunteers were recruited to the study sponsored by St
eorge’s University of London, approved by St George’s Research
thics Committee (reference 06/Q0803/61). Prior formal review
y the UK Competent Authority for regulating clinical trials, the
edicines and Healthcare products Regulatory Agency (MHRA),
onﬁrmed that this basic science challenge study was not a clinical
rial as deﬁned by UK and European Union legislation. To maxi-
ize subject safety the study was conducted in compliance with
rinciples of Good Clinical Practice. The study is registered on Clin-
calTrials.gov (NCT01074775).
Subjects were considered eligible for challenge if they were
8–45years of age, in goodhealth as determinedbymedical history
nd physical examination, had no clinically signiﬁcant abnormality
fhematologyandbiochemistrybloodpanels andwerenegative for
uman immunodeﬁciency virus antibody, p24 antigen and nucleic
cids; hepatitis B virus surface antigen and hepatitis C virus anti-
ody. Subjects were excluded if they had any contraindication
o BCG vaccination according to the Manufacturer’s Data Sheet;
ad hypersensitivity to any component of the vaccine, severe or
ultiple allergies; had cardiological, respiratory or neurological
isease, a known impairmentof immune functionorwere receiving
mmunosuppressive therapy; had acute infections; were pregnant
r lactating, or capable of becoming pregnant and did not agree
o have pregnancy testing before immunization and take effec-
ive contraception for the duration of the study; had a problem
ith substance abuse; had received an investigational agentwithin
0 days, or been in any other study in the previous 6 months; or
ere unlikely to complete the study. All subjects provided writ-
en informed consent before entering screening. Skin testing with
uriﬁed Protein Derivative (PPD, Heaf or Mantoux test) was not
erformed on subjects to avoid stimulating a circulating T-cell
esponse or gene activation by immune recall.
.2. Oral gut infection challenges
Individual batches of sealed, single dose glass vials contain-
ng liquid suspension of 100mg viable BCG Moreau Rio de Janeiro
approximately 107 viable bacilli) in 5mL 1.5% sodium glutamate
olution were supplied directly by Fundac¸ão Ataulpho de Paiva,
razil, and maintained at 2–8 ◦C. The same batch was used for each
hallenge. Volunteers fasted (except water) for a minimum of 2h
efore taking a single 100mg dose in 5mL, swallowed without
dditional buffer, on days 0, 28 and 49 (it had originally been pro-
osed to have the third challenge on day 56, but due to an overlap
ith holidays this was brought forward to day 21 after the sec-
nd immunization). Volunteers fasted a further 2h, during which
o liquids were allowed in the ﬁrst 30min, while volunteers were
bserved. Apart from oral steroids or other immunosuppressives,
herewereno restrictionsonconcomitantmedications,whichwere
ecorded.
.3. Recording and analysis of symptoms
Following challenge, subjectswere issued semi-structureddiary
ards to record symptoms in an attempt to monitor activation of
nnate immune system or inﬂammatory pathways. This elicited
ymptoms relating to the gastrointestinal and upper respiratory
racts, while allowing free text entry for other symptoms. Subjects
raded symptoms as mild, moderate or severe, which were allo-
ated a score of 1, 2 or 3, respectively. To analyze symptoms in
ssociation with each challenge, the sum of the symptom sever-
ty scores of all symptoms recorded by all subjects on each day in8 (2010) 5427–5431
the ﬁrst 28 days after challenge were summed, to give an aggre-
gate symptom score. The score therefore encapsulates both the
frequency and severity of symptoms on any given day for thewhole
group.
2.4. Interferon gamma (IFN) responses
Peripheral blood mononuclear cells were separated from hep-
arinised blood by Ficoll discontinuous gradient centrifugation and
frozen at −80 ◦C prior to measurement of frequency of IFN-
secreting cells and secretion of IFN into culture supernatant in
response to stimulation with the following antigens: PPD (SSI,
Copenhagen) 5g/mL, Ag85 peptide pool (LUMC, Leiden) 5g/mL
or MPB70 (Lionex, Germany) 5g/mL; and medium alone or
PHA 2g/mL, all in AIMV medium (Invitrogen, UK) containing
penicillin–streptomycin. Brieﬂy, 1.5×105 cells/well were stimu-
lated for 7 days in 96-well plates at 37 ◦C and 5% CO2 in a
humidiﬁed incubator with antigens or controls, and concentration
of supernatant IFNmeasuredbyELISAkit (U-CyTech,Netherlands)
expressed in pg/mL using a standard on each plate (NIBSC control
Human IFN rDNA derived, 88/606, NIBSC, UK) and SoftMax soft-
ware. For ELISPOT, 1×106 cells/well (for PHA 3.6×105 cells/well)
were ﬁrst stimulated for 18h in 48-well plates at 37 ◦C and 5%
CO2 in a humidiﬁed incubator with antigens or controls, and
transferred to PVDF-backed 96-well plates (MAHA S45, Millipore,
UK) coated with 5g/ml anti-human IFN mAb 1-D1K (Mabtech,
3420-3-1000) for a further 18h incubation. Responder cells were
detected by sequential incubation with 5g/ml anti-human IFN
mAb biotinylated (Mabtech, 3420-6-250), strepdavidin–alkaline
phosphatase (Mabtech, 3310-10), and BCIP/NBT (Sigma, B5655),
and spots countedonanautomated reader (ViruSpot Elispot reader,
AID UK). Values are reported as number of spot forming cells above
backgroundnumber in unstimulatedwells, or pg/mL IFN in super-
natant after subtraction of level in unstimulated wells.
2.5. Measurement of gene expression proﬁles
Subjects returned to the study site at predeﬁned times (Table 1)
to have blood drawn. Whole blood was drawn directly into PAX-
gene Blood RNA System tubes (PreAnalytiX, BD, UK) and RNA
extracted according to manufacturer’s instructions before freezing
at−80 ◦C. FollowingQCanalysis, sampleswere selected for ampliﬁ-
cationandhybridization into IlluminaHumanWG-6 V2arrays from
days 0, 2, 4 and 7 after each challenge (see Table 1). Analysis of
whole genome gene expression microarrays was performed with
GeneSpringGX9 (Agilent Technologies). Samples were normalized
using median of all samples baseline transformation and quantile
normalization algorithms. Pathway and Gene Ontology (GO) anal-
ysis were performed with the novel informatics package InnateDB
(www.innatedb.ca). Microarray data has been deposited at Array-
Express, a MIAME compliant public archive at EMBL-EBI (accession
number E-TABM-853).
3. Results
3.1. Symptoms indicating activation of innate or inﬂammatory
mechanisms
Seven subjects (5 male and 2 female, ages 22–39, median 27
years) were recruited to receive three sequential oral BCG Moreau
Rio de Janeiro (approximately 107 viable bacilli) challenges (see
Section 2). All subjects completed all visits. Scoring results of symp-
toms after each vaccination dose are shown in Fig. 1. One subject
reported moderate symptoms (abdominal discomfort and loose
stool), and one reported more severe symptoms (loose stools on
2 days). Other symptoms were mild and non-speciﬁc. Five subjects
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Table 1
Schedule of visits, samples collected and assays performed.
Visita 2 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 21 22 23
Day/month after ﬁrst challenge 0 2 4 7 14 21 28 30 32 35 42 49 51 53 56 63 70 74 6 months 9 months 12 months
BCG challenge X X X
PAXGeneb x x x x x x x x x x x x x x x x x x x x x
Arraysc X X X X X X X X X X X X




















aa Study visit 14 was omitted.
b Samples of blood taken into PAXGene tubes, RNA extracted and analysis of con
c Analysis of RNA by Illumina microarray performed for these time points.
d PBMCs separated and in vitro culture for IFN secretion in response to antigen s
eported upper respiratory tract symptoms after theﬁrst challenge,
one after the second, and one after the third. After each challenge
our (different) subjects recordedgastrointestinal symptoms. Inter-
stingly, the frequency and persistence of symptoms was highest
fter the ﬁrst challenge (see Fig. 1, total 28-day aggregate score:
0). After the second challenge there were fewer symptoms con-
ned mainly to the ﬁrst 4 days, with a 28-day aggregate score of
6. After the third challenge there was the lowest number of symp-
oms, present as a low-level background with an aggregate score
f 24.
ig. 1. Symptoms after each challenge infection. The symptoms recorded in the
iary cards were graded by severity (1, 2 or 3) and a total severity score from all
ymptoms calculated by adding all the scores recorded by all subjects on each day
ver the ﬁrst 28 days after the ﬁrst and third challenges, and 21 days after the
econd challenge (as the third challenge was brought forward to 21 days after the
econd). The aggregate score is the sumof all daily scores after each challenge. Score
s higher after the ﬁrst does, indicating activation of innate immunity, but decreases
fter following doses.d purity performed for these time points.
ation performed for these time points.
3.2. Adaptive cell mediated immune responses
All subjects had received parenteral immunization with BCG
in the past, and therefore IFN secretion in response to antigen
stimulation could be detected at baseline, as expected (Fig. 2).
There was little increase in the frequency of cells responding to
PPD or Ag85 stimulation detected by ELISPOT until 6 months
after the ﬁrst challenge (3 months after the third—Fig. 2A).
This late onset elevated response to PPD persisted until 12
months, whereas that to Ag85 declined from a peak at 6 months,
possibly a result of the larger variety of antigens present in
PPD.
The detection of IFN secretion into supernatant after 7 days in
vitro stimulationwas generally less sensitive thanELISPOT (Fig. 2B),
although there was a trend to a response to PPD and Ag85, peak-
ing at 12 and 6 months, respectively, with no response detected to
MPB70.
3.3. Gene expression analysis using microarrays
Microarray analysis of whole blood from vaccinated individ-
uals showed remarkably limited statistically relevant change in
gene expression following each of the vaccine challenges. Out of
>48,000 probes, only 6 and 9 genes were signiﬁcantly differentially
expressed at both days 4 and 7, respectively, after the ﬁrst chal-
lenge, compared to day 0 and all these genes were down-regulated
(Table 2). Importantly, further challenges didnot detectably change
gene expression. No pathway or GO term was over-represented
on day 4. However, at day 7, an over-representation of GO terms
related to cytoskeleton (p-value 0.008) and IL6 receptor activity
(2 genes, p-value 0.01) could be observed. This correlates with
pathway analysis, which showed over-representation of IL6 (2
genes,p-value0.0027) signalingand ‘Vibrio choleraeandpathogenic
Escherichia coli (both EPEC and EHEC) infection’ pathways (3 genes,
p-values 0.017 and 0.016, respectively), as described in Innat-
eDB (www.innatedb.ca) (Table 2). Taken together, these results
suggest a lack of signiﬁcant reactogenicity to the vaccine but
enhanced resistance to re-challenge, correlating with the clinical
results.
4. Discussion
In the present study we were interested in proﬁling aspects
of innate immune activation by repeated oral challenge infection
of healthy volunteers with M. bovis BCG Moreau Rio de Janeiro
vaccine. The oral challenge infections were generally only mildly
reactogenic. Scoring of clinical symptoms showed a higher score
after the ﬁrst challenge. Thus, it would appear, based on clini-
cal symptoms, that the ﬁrst challenge induced the highest acute
activation of inﬂammatory mechanisms, with a shorter burst after
the second challenge, and no clinically detectable activity after the
third.
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Fig. 2. Immune response to challenge infection. Frequency of antigen-speciﬁc cell mediated immune responses for individual subjects at various time points after oral

























Driangles) measured by ELISPOT assay. Values represent frequency of SFCs in antige
timulated. (B) Concentration of IFN secreted into culture supernatant after 7-day
FN concentration in unstimulated wells.
The peak PPD response detected (1550 spots/106 PBMCs)
as higher than observed previously (450 spots/106 PBMCs at
months) after a single oral dose of the same vaccine given in
large volume buffer solution [5]. The higher level of response
bserved in this study compared to previously published data [5]
ay reﬂect a degree of priming by the ﬁrst two oral challenges,
lthough in this study the ELISPOT assaywas different in that an 18-
pre-incubationwith antigenwas included. No response toMPB70
ntigen was detected prior to oral challenge with BCG Moreau,
ut low-level responses were observed after vaccination. MPB70
s an antigen secreted at high levels by BCG Moreau strain but
ot the BCG Glaxo strain the subjects probably received in child-
ood [6]. The lack of high level MPB70 secretion by BCG Glaxo,
nd thus the lack of immune memory on vaccinated volunteers,
robably explains the previous observation that no responseswere
etectable prior to oral challenge, and when they did occur they
ere lower than recall responses to Ag85 which is expressed at
imilar levels by all strains of BCG [7]. Microarray analysis of gene
xpression correlatedwith the lack of obvious reactogenicity of the
accine, only showingadown-regulationof actin and IL6associated
enes.
able 2
ifferentially expressed genes after oral BCG vaccination.
Day Symbol RefSeq ID Fold change p-Value
4 SNORD13 NR 003041.1 −1.5164351 0.01561
LOC654194 XM 942669.1 −1.8388946 0.0283
LOC641848 XM 935588.1 −1.5313528 0.03607
EEF1B2 NM 021121.3 −1.6000162 0.03859
RPL17 NM 001035006.1 −2.1609983 0.04507
LOC653773 XM 938755.2 −1.9737101 0.04602
7 WDR1 NM 017491.3 −1.57219 0.00793
JAK1 NM 002227.2 −1.5415655 0.00929
IL6R NM 000565.2 −1.5137477 0.01698
TAGAP NM 138810.2 −1.6010119 0.01916
LOC644063 XR 016547.1 −1.7702552 0.02036
ACTG1 NM 001614.2 −1.5455536 0.02069
ACTB NM 001101.2 −1.5035121 0.02776
ARHGAP30 NM 001025598.1 −1.5573095 0.04186
ALDOA NM 184041.1 −1.5015596 0.04596ulated wells after subtraction of frequency in unstimulated wells, per 10 PBMCs
ro stimulation with the different antigens, expressed as pg/mL after subtraction of
The BCG oral challenge model was selected as being safe, asso-
ciated with a mild-moderate degree of reactogenicity in previous
studies, and available as an acceptable commercial formulation
of attenuated M. bovis. A more reactogenic challenge organism
(such as partially attenuated strains of Shigella or Salmonella)
may have given more conclusive results, had an acceptable for-
mulation been available. However, we did observe a decline in
clinical symptoms with each subsequent oral challenge, suggest-
ing a degree of resistance to challenge was developing. The peak
of IFN response seen after the third challenge was higher than
had been observed in the previous study using only one oral dose
[5]. This may imply a degree of priming by the ﬁrst two chal-
lenges and the data suggest that close spacing of oral doses with
live BCG may not be optimal to induce an adaptive response,
especially one that occurs rapidly. However, we designed the
study with the speciﬁc aim that the second and third challenges
should interfere with the previous ones via the innate and not
adaptive immune response. Although there is no direct evidence
that subsequent challenges interfered with the immune responses
to previous challenge, it remains a possible explanation for the
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atively, immune responses to mycobacterial infection may take
onger to develop, and the close spacing of repeat challenges may
ot have given sufﬁcient time for an effective memory response to
evelop before the second and third challenges. As with all studies
sing cellular readouts in humans, there was considerable within-
ubject, and between-subject variation, and further larger studies
ill be needed to conﬁrm the preliminary observations reported
ere.
In conclusion, although the potential of this approach for mon-
toring clinical innate immune responses to gut infection via gene
ctivationwould appear to be limited, oral challenge infectionwith
CG Moreau Rio de Janeiro vaccine is safe and immunogenic in
ealthy volunteers.cknowledgments
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